Explore

Trendline Trendline
Dynaco Europe's Cleanroom Door Innovation Wins Prestigious Award

Dynaco Europe's Cleanroom Door Innovation Wins Prestigious Award

Dynaco Europe's Cleanroom Door Innovation Wins Prestigious Award
Trendline Trendline
Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials
Trendline Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion

Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Trendline Trendline
Gilead Sciences Announces $3 Billion Senior Unsecured Notes Offering for Corporate Expansion

Gilead Sciences Announces $3 Billion Senior Unsecured Notes Offering for Corporate Expansion

Gilead Sciences Announces $3 Billion Senior Unsecured Notes Offering for Corporate Expansion
Trendline Trendline
Varda Space Industries Partners with US Pharma Firm for Space-Based Drug Development

Varda Space Industries Partners with US Pharma Firm for Space-Based Drug Development

Varda Space Industries Partners with US Pharma Firm for Space-Based Drug Development
Trendline Trendline
AI Sourcing Revolutionizes Manufacturing by Enhancing Decision-Making and Supply Chain Resilience

AI Sourcing Revolutionizes Manufacturing by Enhancing Decision-Making and Supply Chain Resilience

AI Sourcing Revolutionizes Manufacturing by Enhancing Decision-Making and Supply Chain Resilience
Trendline Trendline
N-Zyme Biomedical Supports FDA's Drug Repurposing Initiatives for Unmet Medical Needs

N-Zyme Biomedical Supports FDA's Drug Repurposing Initiatives for Unmet Medical Needs

N-Zyme Biomedical Supports FDA's Drug Repurposing Initiatives for Unmet Medical Needs
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges
Trendline Trendline
Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects

Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects

Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects
Trendline Trendline
Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million
Trendline Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026